1,5-Anhydroglucitol和时间范围作为2型糖尿病中糖尿病视网膜病变的补充标记物
Hang Su1,2, Jiaying Ni2, Jingyi Lu2
1Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Diabetes/metabolism research and reviews
|March 6, 2026
概括
较低的1,5-基醇 (1,5-AG) 水平与2型糖尿病患者糖尿病视网膜病变 (DR) 的更高患病率有关. 这种短期的血糖标记可能有助于识别额外的DR风险,特别是在具有良好的时间范围 (TIR) 的患者中.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病学 糖尿病学
- 眼科医生 眼科 眼科
背景情况:
- 持续血糖监测 (CGM) 提供了对血糖控制的见解,但其与传统标记物的整合需要进一步探索.
- 1,5-基醇 (1,5-AG) 反映了在1-2周的血糖控制,一个类似于CGM的时间框架.
- 糖尿病视网膜病变 (DR) 是糖尿病的一个显著的微血管并发症.
研究的目的:
- 为了研究血清1,5-二醇 (1,5-AG) 水平和糖尿病视网膜病变 (DR) 在患有2型糖尿病的成年人中患病率之间的关联.
- 探索1,5-AG是否提供了超出CGM衍生指标的DR额外风险信息,包括范围内的时间 (TIR) 和葡萄糖变化.
主要方法:
- 一项涉及5491名患有2型糖尿病的成年人的横截面研究.
- 参与者根据血清1,5-AG水平进行分类:<6.0微克/毫升,6.0-10.0微克/毫升,≥10.0微克/毫升.
- 分析了CGM数据的时间范围 (TIR) 和可变性指标 (SD,CV,MAGE).
主要成果:
- DR患病率为25.3%,并且随着1,5-AG水平的下降而显著增加 (p<0.001).
- 与1,5-AG≥10.0μg/mL的人相比,1,5-AG<6.0μg/mL的个体,DR的几率增加了1.64倍.
- 低的1,5-AG仍然与不同TIR三角动物的DR风险升高有关,特别是在中高三角动物中.
结论:
- 血清1,5-AG是2型糖尿病中DR患病率的重要独立预测因子.
- 在达到高TIR (≥80%) 的患者中,1,5-AG水平可能为DR风险分层提供额外的见解.
相关概念视频
01:22Diabetes Mellitus: Type 2 and Gestational
5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.6K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.6K
01:06Oral Hypoglycemic Agents: Glinides
784
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
784
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
713
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
713